Suppr超能文献

术前放化疗后远端CT2N0直肠癌的括约肌保留

Sphincter preservation in distal CT2N0 rectal cancer after preoperative chemoradiotherapy.

作者信息

Wasserberg Nir, Kundel Yulia, Purim Ofer, Keidar Andrei, Kashtan Hanoch, Sadot Eran, Fenig Eyal, Brenner Baruch

机构信息

Department of Surgery B, Petach Tikva, 49100, Israel.

Davidoff Cancer Center, Rabin Medical Center, Beilinson Campus, Petach Tikva, 49100, Israel.

出版信息

Radiat Oncol. 2014 Oct 22;9:233. doi: 10.1186/s13014-014-0233-3.

Abstract

BACKGROUND

Preoperative chemoradiotherapy is usually not indicated for cT2N0 rectal cancer. Abdominoperineal resection is the standard treatment for distal rectal tumors. The aim of the study was to evaluate the actual sphincter-preservation rate in patients with distal cT2N0 rectal cancer given neoadjuvant chemoradiotherapy.

METHODS

Data were retrospectively collected for all patients who were diagnosed with distal cT2N0 rectal cancer at a tertiary medical center in 2000-2008 and received chemoradiotherapy followed by surgery (5-7 weeks later).

RESULTS

Thirty-three patients (22 male) of median age 65 years (range, 32-88) were identified. Tumor distance from the anal verge ranged from 0 to 5 cm. R0 resection with sphincter preservation was accomplished in 22 patients (66%), with a 22% pathological complete response rate. Median follow-up time was 62 months (range 7-120). There were no local failures. Crude disease-free and overall survival were 82% and 86%, respectively. Factors associated with sphincter preservation were tumor location (OR=0.58, p=0.02, 95% CI=0.37-0.91) and pathological downstaging (OR=7.8, p=0.02, 95% CI=1.35-45.85). Chemoradiotherapy was well tolerated.

CONCLUSION

High rates of sphincter preservation can be achieved after preoperative chemoradiotherapy for distal cT2N0 rectal cancer, with tolerable toxicity, without compromising oncological outcome.

摘要

背景

术前放化疗通常不适用于cT2N0期直肠癌。腹会阴联合切除术是低位直肠肿瘤的标准治疗方法。本研究的目的是评估接受新辅助放化疗的低位cT2N0期直肠癌患者的实际保肛率。

方法

回顾性收集2000年至2008年在一家三级医疗中心被诊断为低位cT2N0期直肠癌并接受放化疗后手术(5至7周后)的所有患者的数据。

结果

共纳入33例患者(22例男性),中位年龄65岁(范围32 - 88岁)。肿瘤距肛缘距离为0至5 cm。22例患者(66%)实现了保肛的R0切除,病理完全缓解率为22%。中位随访时间为62个月(范围7 - 120个月)。无局部复发。粗无病生存率和总生存率分别为82%和86%。与保肛相关的因素为肿瘤位置(OR = 0.58,p = 0.02,95%CI = 0.37 - 0.91)和病理降期(OR = 7.8,p = 0.02,95%CI = 1.35 - 45.85)。放化疗耐受性良好。

结论

术前放化疗治疗低位cT2N0期直肠癌后可实现较高的保肛率,毒性可耐受,且不影响肿瘤学结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c136/4215010/1f3ee5034f8e/13014_2014_233_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验